Exelixis
Exelixis Gains European Cometriq Nod with Note about Low Response in Non-RET Mutated MTC Patients
Premium
Originally published March 25.
The European Commission has approved Cometriq (cabozantinib) as a treatment for medullary thyroid cancer (MTC) patients.
Originally published Dec. 23.
EU's CHMP Issues Positive Opinion Exelixis' Cometriq for Medullary Thyroid Cancer
Researchers Use 'NanoVelcro' Chip to Capture Prostate Cancer CTCs for Single-Cell Sequencing
Premium
A team led by investigators at Cedars-Sinai Medical Center and the University of California, Los Angeles has developed a new approach for analyzing circulating tumor cells obtained from prostate cancer patients using chip- and sequencing-based applications.
MDx/CDx Focus: EC Approves Kalydeco; Cabozantinib in PGx-Targeted NSCLC; Ponatinib, CDx FDA Filing
Premium
European Commission Approves Vertex's Personalized CF Drug Kalydeco
Gaithersburg West Master Plan, Ben Franklin Technology Partners, University of Houston Institute of Biomedical Research, Connecticut Economic Development Consolidations, South San Francisco Life Sciences Career Fair, New York City Biotechnology Tax Credit